
Cellectar Biosciences, Inc.
NASDAQ:CLRB
7.11 (USD) • At close June 30, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Cellectar Biosciences, Inc. |
Symbool | CLRB |
Munteenheid | USD |
Prijs | 7.11 |
Beurswaarde | 327,628,089 |
Dividendpercentage | 0% |
52-weken bereik | 6.5 - 94.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. James V. Caruso |
Website | https://www.cellectar.com |
An error occurred while fetching data.
Over Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)